Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan

NCT00219375 ↗

Phase 4 Completed 649 enrolled Ono Pharmaceutical Co., Ltd.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to confirm the efficacy and safety of sivelestat in patients with acute lung injury associated with systemic inflammatory response syndrome. The results will be compared to the study with conventional treatment without sivelestat.

Timeline

Start: 2004-06
Primary completion: 2007-07
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sivelestat	Small molecule	0.2 mg/kg	Intravenous

Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan

Summary

Timeline

Drugs

Indications